Lipitor Generic Rights May be Sold Should Ranbaxy Laboratories's Approval Come Too Late

Ranbaxy Laboratories Ltd. (RBXY) may sell rights to make a generic version of Pfizer Inc. (PFE)’s Lipitor, the world’s best-selling medicine, should it fail to win timely U.S. approval for the cholesterol pill, Credit Suisse AG said. A legal settlement with Pfizer gave Ranbaxy six months’ exclusivity to market generic Lipitor in the U.S. Delays in Food and Drug Administration approval may prevent the Indian company from selling its copies as planned from Nov. 30, Credit Suisse equity analysts Edward J. Kelly and Rajat Suri said yesterday.

Back to news